[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368171-105":59,"doc-detail-368171-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","distinct-mrna-expression-profiles-and-mirna-regulators-of-the-pi3kaktmtor-pathway-in-breast-cancer-insights-into-tumor-progression-and-therapeutic-targets","Distinct mRNA expression proﬁles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer - insights into tumor progression and therapeutic targets","","Breast cancer’s molecular complexity across subtypes drives tumor progression and contributes to mortality. This clinical trial investigates differential expression of genes and microRNAs (miRNAs) within the PI3K/AKT/mTOR signaling pathway, a key regulator of cancer progression. Tumor tissues from five breast cancer subtypes—luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-positive, and triple-negative (TNBC)—are compared with non-cancerous tissues using microarray and qRT-PCR for mRNA/miRNA profiling, complemented by bioinformatic prediction of miRNA-mRNA interactions. Upregulated genes are identified across subtypes, with TNBC and HER2-positive showing the strongest changes, including COL1A1, COL4A1, PIK3CA, PIK3R1, and mTOR. Specific miRNAs, including miR-190a-3p, miR-4729, and miR-19a-3p, are proposed to regulate these genes and influence pathway activity. Findings suggest pathway-miRNA interactions are critical in aggressive subtypes and may support biomarkers and therapeutic targeting, pending further functional validation.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/distinct-mrna-expression-profiles-and-mirna-regulators-of-the-pi3kaktmtor-pathway-in-breast-cancer-insights-into-tumor-progression-and-therapeutic-targets/368171/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/distinct-mrna-expression-profiles-and-mirna-regulators-of-the-pi3kaktmtor-pathway-in-breast-cancer-insights-into-tumor-progression-and-therapeutic-targets/368171.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What biological pathway is the study centered on in breast cancer?","Question",{"text":112,"@type":113},"The study focuses on the PI3K/AKT/mTOR signaling pathway and how its activity relates to gene and miRNA expression changes across subtypes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were mRNA and miRNA differences measured between tumor and non-cancer tissues?",{"text":117,"@type":113},"Tumor tissues from multiple breast cancer subtypes and non-cancer tissues were analyzed using microarray and qRT-PCR for mRNA and miRNA profiling, with bioinformatics used to predict miRNA-mRNA interactions.",{"name":119,"@type":110,"acceptedAnswer":120},"Which breast cancer subtypes showed the most significant expression changes?",{"text":121,"@type":113},"TNBC and HER2-positive cancers showed the most significant changes, including overexpression of key pathway-related genes such as PIK3CA, PIK3R1, and mTOR.",{"name":123,"@type":110,"acceptedAnswer":124},"What do the results suggest about potential clinical applications?",{"text":125,"@type":113},"The identified miRNAs and mRNAs may serve as biomarkers for diagnosis and treatment, and they provide a foundation for targeted therapies aimed at modulating the PI3K/AKT/mTOR pathway, though functional validation is still required.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368171,1790203902,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","TYPE Clinical Trial  \nPUBLISHED 09 January 2025 DOI 10.3389/fonc.2024.1515387  \nOPEN ACCESS  \nEDITED BY  \nCatalin Marian,  \nVictor Babes University of Medicine and Pharmacy, Romania  \nREVIEWED BY  \nAnca Maria Cimpean,  \nVictor Babes University of Medicine and Pharmacy, Romania  \nGiovannino Silvestri,  \nUniversity of Maryland Medical Center, United States  \n*CORRESPONDENCE  \nTomasz Sirek  \n [drtkierka@gmail.com](drtkierka@gmail.com)  \nRECEIVED 22 October 2024  \nACCEPTED 17 December 2024  \nPUBLISHED 09 January 2025  \nCITATION  \nSirek T, Kro´l-Jatre˛ga K, Borawski P, Zmarzły N, Boron´ D, Ossowski P, Nowotny-Czupryna O, Boron´ K, Janiszewska-Bil D, Mitka-Krysiak E and Grabarek BO (2025) Distinct mRNA expression proﬁles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.  \nFront. Oncol. 14:1515387 .  \ndoi: 10.3389/fonc.2024.1515387  \nCOPYRIGHT  \n© 2025 Sirek, Kro´ l-Jatre˛ga, Borawski, Zmarzły, Boron´ , Ossowski, Nowotny-Czupryna, Boron´, Janiszewska-Bil, Mitka-Krysiak and Grabarek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDistinct mRNA expression proﬁles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets  \nTomasz Sirek 1,2*, Katarzyna Kro´ l-Jatre˛ ga 1,2,  \nPrzemysław Borawski 3, Nikola Zmarzły4, Dariusz Boro ´n4,5,6,7, Piotr Ossowski 4, Olga Nowotny-Czupryna 4, Kacper Boro ´n1, Dominika Janiszewska-Bil 4, El˙zbieta Mitka-Krysiak 4 and Beniamin Oskar Grabarek 4,8  \n1 Department of Plastic Surgery, Faculty of Medicine, Academia of Silesia, Katowice, Poland,  \n2 Department of Plastic and Reconstructive Surgery, Hospital for Minimally Invasive and Reconstructive Surgery in Bielsko-Biała, Bielsko-Biala, Poland, 3 Independent Researcher, Włocławek, Poland,  \n4 Department of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Go´rnicza, Poland, 5 Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Krako´w, Poland, 6 Department of Gynecology and Obstetrics, TOMMED Specjalisci od Zdrowia, Katowice, Poland, 7 University of Economics and Humanities in Warsaw, Warszawa, Poland, 8 Department of Molecular, Biology Gyncentrum Fertility Clinic, Katowice, Poland  \nBackground: Breast cancer remains a leading cause of mortality among women, driven by the molecular complexity of its various subtypes. This study aimed to investigate the differential expression of genes and miRNAs involved in the PI3K/ AKT/mTOR signaling pathway, a critical regulator of cancer progression.  \nMethods: We analyzed tumor tissues from ﬁve breast cancer subtypes—luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-positive, and triplenegative breast cancer (TNBC)—and compared them with non-cancerous tissues. Microarray and qRT-PCR techniques were employed to proﬁle mRNAsand miRNAs, while bioinformatic tools predicted miRNA-mRNA interactions. Statistical analysis was performed with a statistical signiﬁcance threshold (p) \u003C 0 .05.  \nResults: We identiﬁed several upregulated genes across all subtypes, with TNBC and HER2-positive cancers showing the most signiﬁcant changes. Key genes such as COL1A1 , COL4A1 , PIK3CA, PIK3R1, and mTOR were found to be overexpressed, correlating with increased cancer aggressiveness. miRNA analysis revealed that miR-190a-3p, miR-4729, and miR-19a-3p potentially regulate these genes, inﬂuencing the PI3K/AKT/mTOR pathway. For instance, reduced expression of miR-190a-3p may contribute to the overexpression of","cbCairWexLm2YjUR","https://ap.wps.com/l/cbCairWexLm2YjUR","pdf",8950950,22,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What biological pathway is the study centered on in breast cancer?\",\"answer\":\"The study focuses on the PI3K/AKT/mTOR signaling pathway and how its activity relates to gene and miRNA expression changes across subtypes.\"},{\"question\":\"How were mRNA and miRNA differences measured between tumor and non-cancer tissues?\",\"answer\":\"Tumor tissues from multiple breast cancer subtypes and non-cancer tissues were analyzed using microarray and qRT-PCR for mRNA and miRNA profiling, with bioinformatics used to predict miRNA-mRNA interactions.\"},{\"question\":\"Which breast cancer subtypes showed the most significant expression changes?\",\"answer\":\"TNBC and HER2-positive cancers showed the most significant changes, including overexpression of key pathway-related genes such as PIK3CA, PIK3R1, and mTOR.\"},{\"question\":\"What do the results suggest about potential clinical applications?\",\"answer\":\"The identified miRNAs and mRNAs may serve as biomarkers for diagnosis and treatment, and they provide a foundation for targeted therapies aimed at modulating the PI3K/AKT/mTOR pathway, though functional validation is still required.\"}]","Distinct mRNA expression proﬁles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer - insights into tumor progression and therapeutic targets | PDF",1790175402,55,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b25108f2bd1710f6a45f176c5810ee9.webp",983,1389,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5d05b38a1093b8681442be1f5fc238f.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/549ac634f12956771c67f620aca2b775.webp",981,1386,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9598f8ead5dcd9c5a10ddd7f47fd3024.webp",980,1385]